Eli Lilly’s Zepbound proved more effective than Novo Nordisk’s Wegovy in a new head-to-head trial, though both medications resulted in substantial weight loss. The trial, call

A new study shows that people Zepbound lost about 50% more weight than those using Wegovy. It was the first head-to-head trial of the blockbuster weight-loss medications.

Those who take tirzepatide, the drug sold as Zepbound and Mounjaro, could lose more weight than those who take semaglutide, known as Ozempic and Wegovy, according to new research.